advertisement
Hitzl W 17
Showing records 1 to 17 | Display all abstracts from Hitzl W100377 Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria-Which One Is Most Suitable?
Rendl G
Cancers 2022; 14:
100383 Resveratrol Microencapsulation into Electrosprayed Polymeric Carriers for the Treatment of Chronic, Non-Healing Wounds
De Pieri A
Pharmaceutics 2022; 14:
100745 Neural Networks Modeling for Prediction of Required Resources for Personalized Endourologic Treatment of Urolithiasis
Huettenbrink C; Hitzl W
Journal of personalized medicine 2022; 12:
100383 Resveratrol Microencapsulation into Electrosprayed Polymeric Carriers for the Treatment of Chronic, Non-Healing Wounds
Ocorr K
Pharmaceutics 2022; 14:
100377 Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria-Which One Is Most Suitable?
Schweighofer-Zwink G
Cancers 2022; 14:
100745 Neural Networks Modeling for Prediction of Required Resources for Personalized Endourologic Treatment of Urolithiasis
Pahernik S
Journal of personalized medicine 2022; 12:
100383 Resveratrol Microencapsulation into Electrosprayed Polymeric Carriers for the Treatment of Chronic, Non-Healing Wounds
Jerreld K
Pharmaceutics 2022; 14:
100377 Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria-Which One Is Most Suitable?
Sorko S
Cancers 2022; 14:
100383 Resveratrol Microencapsulation into Electrosprayed Polymeric Carriers for the Treatment of Chronic, Non-Healing Wounds
Lamoca M
Pharmaceutics 2022; 14:
100377 Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria-Which One Is Most Suitable?
Gallowitsch HJ
Cancers 2022; 14:
100745 Neural Networks Modeling for Prediction of Required Resources for Personalized Endourologic Treatment of Urolithiasis
Kubitz J
Journal of personalized medicine 2022; 12:
100383 Resveratrol Microencapsulation into Electrosprayed Polymeric Carriers for the Treatment of Chronic, Non-Healing Wounds
Hitzl W
Pharmaceutics 2022; 14:
100377 Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria-Which One Is Most Suitable?
Hitzl W
Cancers 2022; 14:
100745 Neural Networks Modeling for Prediction of Required Resources for Personalized Endourologic Treatment of Urolithiasis
Popeneciu V; Ell J
Journal of personalized medicine 2022; 12:
100377 Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria-Which One Is Most Suitable?
Reisinger D
Cancers 2022; 14:
100383 Resveratrol Microencapsulation into Electrosprayed Polymeric Carriers for the Treatment of Chronic, Non-Healing Wounds
Wuertz-Kozak K
Pharmaceutics 2022; 14:
100377 Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria-Which One Is Most Suitable?
Pirich C
Cancers 2022; 14:
